Back to journals
Academic Journal

Journal of Medical Economics

2 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States

This real-world (n=269) analysis of esketamine (Spravato) use finds nearly 50% of patients had their first pharmacy claim approved. Of those approved, 45% had eight or more treatment sessions (as recommended), though spread over 85 days (versus 28 per the label). Patients had lower health utilization, but this could be due to factors outside of the esketamine treatment (e.g. regression to the mean).

Published
Journal
Journal of Medical Economics
Authors
Zhdanava, M., Teeple, A., Pilon, D., Shah, A., Caron-Lapointe, G., Joshi, K.
Open Accessindividual

Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on Esketamine intranasal spray and covered by US commercial health plans

This analysis of health outcomes (n=269) of those treated with esketamine for treatment-resistant depression (TRD) finds a trend (but not significant differences) towards lower healthcare costs. Dosing intervals (of ketamine) were longer than recommended on the label.

Published
Journal
Journal of Medical Economics
Authors
Joshi, K., Pilon, D., Shah, A., Holiday, C., Karkare, S., Zhdanava, M.

Quick Facts

Papers Indexed
2
h-Index
58
Open Access
No
Publisher
Taylor & Francis
Country
United Kingdom
Website
Visit